Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - EXTended Criteria Donors (BENEFIT-EXT).

Trial Profile

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - EXTended Criteria Donors (BENEFIT-EXT).

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2018

At a glance

  • Drugs Belatacept (Primary) ; Ciclosporin
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Acronyms BENEFIT-EXT
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 06 Jun 2018 Results (n=870) assessing the effect of belatacept on the immunogenicity of individual HLA mismatches from BENEFIT and BENEFIT-EXT Trial cohorts presented at the 2018 American Transplant Congress
    • 06 Jun 2018 Results (n=1129) of BENEFIT and BENEFIT-EXT trials determining relative immunogenecity presented at the 2018 American Transplant Congress
    • 06 Mar 2018 Results of post hoc analysis of BENEFIT and BENEFIT-EXT trials assessing association between belatacept belatacept based immunosuppression and incidence of de novo DSA development published in the American Journal of Transplantation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top